The 3rd China Pharma, Biotech & Chemical IP Forum and Innovation Exhibition
May 25-27, 2012
China Medical City, Taizhou, China

Endorsed by
The State Intellectual Property Office of the People's Republic of China (SIPO)
The Ministry of Health of the People's Republic of China (MOH)
Chinese Academy of Sciences

Co-organized by
Chinese American Chemical Society
American Chemical Society
中国知识产权研究会 (China Intellectual Property Society)
中国药学会医药知识产权研究专业委员会 (IPR of Chinese Pharmaceutical Association)
江苏省知识产权局 (Jiangsu provincial intellectual property office of PRC)

Hosted by:  China Medical City

Inspired by the success of the 1st and 2nd Beijing International Pharmaceutical and Chemical Intellectual Property Forums, the original organizing parties will hold The 3rd China IP Forum, which is again endorsed and supported by China’s State Intellectual Property Office (SIPO) and the Ministry of Health (MOH). A new addition to the organizing parties is the Intellectual Property Office of Jiangsu Province, the regional bureau of SIPO. This Forum also gains the support and endorsement from the Chinese Academy of Sciences, the preeminent research institute in China.

The 3rd China IP Forum will expand its format and change its venue to reflect the fast development of Chinese Patent Law and China’s growing investment in R&D. The Forum will focus on "R&D Patent Protection, Innovation Transfer and Commercialization" and add a specially designed Innovation Exhibition and Networking Session to allow participating companies to exhibit their innovations in the areas of pharmaceutical and biological products, medical devices, nutraceuticals, traditional Chinese medicines, as well as all chemical products. This will be a great and unique opportunity to network with many of China’s best innovative companies in the healthcare and chemical industries.

The 3rd China IP Forum’s mission is to provide an opportunity to the IP community to discuss the next wave of development in China’s rapidly developing IP environment. The 1st Forum introduced China as the world’s newest IP frontier and highlighted many possibilities not yet realized in China and its IP system. The 2nd Forum focused on the Third Amendment to China’s Patent Law and its similarities and differences to other developed countries’ patent laws, thereby offering an early round-table into how best to navigate China’s patent law. The 2nd Forum also provided insightful presentations and discussions from US and European experts to give Chinese IP practitioners the opportunity to learn about IP laws and issues that affect the pharmaceutical and chemical industries in the largest world markets.

The 3rd China IP Forum promises to continue setting the trend in Chinese IP seminars by covering the next big developing area in Chinese IP. The Chinese market has become a strategic focus in the innovative healthcare industry. In November 2010, SIPO published its ten year patent plan entitled "National Patent Development Strategy 2011-2020", which outlines an agenda to realize China’s goal to be an innovation-based country. As part of its IP strategy, China has set a target to file two million patent applications annually by 2015. The results of China’s push to become a leading innovator are already visible. According to the World Intellectual Property Organization, China's international patent
filings under WIPO's Patent Cooperation Treaty (PCT) surged by 56.2 percent in 2010, leading the global growth in international patent filings, which increased by 4.8 percent over the same period. The increased innovation and patent filings in China means that there are companies and institutions asking such questions as: Where should I file patents outside of China? How do I get patents in the biggest markets? Once I have a patent, what do I do with it? How do I best use my patent as an asset inside and outside of China? The 3rd China IP Forum will discuss these questions.

The 3rd China IP Forum will provide presentations from experts from the U.S., Europe, Japan and other emerging market countries, such as Brazil and Russia, who will address these and other questions. Additionally, the 3rd China IP Forum will provide opportunities for focused networking in business development and technology transfer with Chinese research-based pharmaceutical and biotech companies, research institutions and universities with IP-protected inventions.

The meeting will take place in China Medical City (CMC), Taizhou, located north of Shanghai. CMC is the only central government authorized/sponsored national hub dedicated exclusively to biomedical R&D and manufacturing where hundreds of major international and domestic corporations in pharmaceutical, biomedical, biochemical and bio-tech enterprises operate. CMC is the largest biomedical cluster in China.